Cancer

Title
The Study of a Commercial Medication in Individuals with Kidney Cancer
Trial Number
203579061511
Number of Participants
1,170
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

Patients must be 18 years of age or older with histologically or cytologically confirmed renal cell carcinoma (clear-cell or non-clear-cell allowed, but collecting duct or medullary carcinomas excluded).

Patients must be considered pathologically either intermediate high-risk or very high-risk. Patients must not have a history of distant metastases. Patients with microvascular invasion of the renal vein of any grade or stage (as long as M0) also are eligible.

Purpose

The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.